The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,997,957 |
| Non-cash stock-based compensation | 829,095 |
| Depreciation and amortization | 20,099 |
| Gain on disposal of property and equipment | 0 |
| Change in carrying amount of right-of-use asset | 173,681 |
| Prepaid expenses and other assets | -530,000 |
| Accounts payable, accrued liabilities and other liabilities | 459,871 |
| Deferred revenue | 370,160 |
| Operating lease liabilities | -195,010 |
| Net cash used in operating activities | -9,810,061 |
| Proceeds from sale of property and equipment | 0 |
| Acquisitions of property and equipment | 2,899 |
| Net cash used in investing activities | -2,899 |
| Proceeds from issuance of equity under sepa | 244,018 |
| Net cash provided by financing activities | 244,018 |
| Effect of exchange rate changes on cash and cash equivalents | 15,681 |
| Net change in cash and cash equivalents | -9,553,261 |
| Cash and cash equivalents, beginning of year | 40,359,738 |
| Cash and cash equivalents, end of year | 30,806,477 |
MEDICINOVA INC (MNOV)
MEDICINOVA INC (MNOV)